夏毓航,袁 莉,胡 灿,等.SLC34A2(NaPi-Ⅱb)在胃癌中的表达及其与临床病理特征及预后的关系[J].肿瘤学杂志,2022,28(4):264-271.
SLC34A2(NaPi-Ⅱb)在胃癌中的表达及其与临床病理特征及预后的关系
Expression of SLC34A2(NaPi-Ⅱb) in Gastric Cancer and Its Relationship with Clinicopathological Features and Prognosis
投稿时间:2021-11-14  
DOI:10.11735/j.issn.1671-170X.2022.04.B003
中文关键词:  SLC34A2  胃肿瘤  病理特征  预后
英文关键词:SLC34A2  gastric neoplasms  clinicopathological features  prognosis
基金项目:国家自然科学基金 (82074245);浙江省中医药科技计划项目 (2018ZY006)
作者单位
夏毓航 浙江中医药大学第一临床医学院 
袁 莉 中国科学院大学附属肿瘤医院(浙江省肿瘤医院)中国科学院基础医学与肿瘤研究所 
胡 灿 浙江中医药大学第一临床医学院 
王 以 浙江中医药大学第一临床医学院 
摘要点击次数: 671
全文下载次数: 120
中文摘要:
      摘 要:[目的]探讨溶质载体转运蛋白SLC34A2(NaPi-Ⅱb) 在胃癌中的表达及其与临床病理特征及预后的关系。[方法] 选取手术切除的胃癌标本140例,同时收集胃癌组织和癌旁组织以进行对照分析。采用组织芯片技术(TMT)构建胃癌组织及配对癌旁组织石蜡组织芯片,用免疫组化法检测该芯片中SLC34A2的表达。[结果] 在受检测的140例胃癌患者中,SLC34A2在肿瘤组织中的表达明显高于癌旁组织(P=0.019)。胃癌组织中SLC34A的表达与肿瘤大小(χ2=5.002,P=0.025)、病理类型(χ2=5.744,P=0.017)、肿瘤标志物CEA(χ2=4.452,P=0.035)、PD-L1表达(χ2=4.776,P=0.029)密切相关。SLC34A2高表达患者的5年生存率明显低于低表达患者(38.9% vs 56.0%,P=0.010)。多因素分析显示SLC34A2高表达是胃癌患者预后的独立危险因素。[结论] SLC34A2在胃癌组织中高表达,并与预后不良相关,可能是胃癌诊疗的潜在靶点。
英文摘要:
      Abstract:[Objective] To investigate the expression of solute carrier transporter SLC34A2(NaPi-Ⅱb) in gastric cancer and its relationship with clinicopathological characteristics and prognosis. [Methods] A total of 140 gastric cancer specimens who accepted the surgical resection were selected. Meanwhile, gastric cancer tissues and paracancerous tissues were collected for comparative analysis. Tissue Microarray Technique(TMT) was used to construct gastric cancer tissues and paired paracancerous tissues paraffin tissue chips, and immunohistochemical method was used to detect the expression of SLC34A2 in the chip. [Results] Among 140 gastric cancer patients, it was found that the expression of SLC34A2 in tumor tissues was significantly higher than that in paracancerous tissues(P=0.019). The expression of SLC34A2 in gastric cancer tissue was closely related to tumor size(diameter)(χ2=5.002, P=0.025), pathological type (χ2=5.744, P=0.017), carcinoma embryonic antigen(χ2=4.452, P=0.035), PD-L1 expression(χ2=4.776, P=0.029). The 5-year OS of patients in SLC34A2 high expression group was significantly lower than that of the low expression group(P=0.010). Multivariate analysis showed that the high expression of SLC34A2 was an independent risk factor for the prognosis of gastric cancer patients. [Conclusion] SLC34A2 is highly expressed in gastric cancer tissues and associated with poor prognosis. It may be a potential target for the diagnosis and treatment of gastric cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器